利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.051 秒)

    Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
    13.
    发明申请
    Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY 审中-公开
    Fc-γ-RIIb-SPECIFIC Fc抗体

    公开(公告)号：US20140093496A1

    公开(公告)日：2014-04-03

    申请号：US14001218

    申请日：2012-02-24

    申请人： Futa Mimoto ,  Taichi Kuramochi ,  Tomoyuki Igawa ,  Hitoshi Katada ,  Shojiro Kadono

    发明人： Futa Mimoto ,  Taichi Kuramochi ,  Tomoyuki Igawa ,  Hitoshi Katada ,  Shojiro Kadono

    IPC分类号： C07K16/18 ,  C07K16/08

    CPC分类号： C07K16/2866 ,  C07K16/08 ,  C07K16/18 ,  C07K16/303 ,  C07K2317/524 ,  C07K2317/72

    摘要： An objective of the present invention is to provide a polypeptide containing an Fc region having maintained or decreased binding activities towards both allotypes of FcγRIIa, types H and R, and having enhanced FcγRIIb-binding activity in comparison with a parent polypeptide; a pharmaceutical composition containing the polypeptide; an agent for treating or preventing immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method for maintaining or decreasing binding activities towards both allotypes of FcγRIIa and enhancing the FcγRIIb-binding activity. Specifically, it is found that a polypeptide containing an antibody Fc region that has an alteration of substituting Pro at position 238 (EU numbering) with Asp or Leu at position 328 (EU numbering) with Glu enhances FcγRIIb-binding activity, and maintains or decreases binding activities towards both allotypes of FcγRIIa, types H and R. It is also found that a polypeptide containing an antibody Fc region that contains an alteration of substituting Pro at position 238 (EU numbering) with Asp and several other alterations, enhances FcγRIIb-binding activity, and maintains or decreases binding activities towards both allotypes of FcγRIIa, types H and R.

    摘要翻译： 本发明的目的是提供一种多肽，其含有与亲本多肽相比具有增强的FcγRIIb结合活性的FcγRIIa，H型和R型两种的同种异型的具有维持或降低的结合活性的Fc区; 含有该多肽的药物组合物; 用于治疗或预防包括该药物组合物的免疫性炎性疾病的药剂; 其制造方法; 以及用于维持或减少对FcγRIIa的同种异型的结合活性并增强FcγRIIb结合活性的方法。 具体地说，发现含有在位置238上用Asp或Leu取代第238位（EU编号）的抗体Fc区的多肽与Glu的EU编号增强FcγRIIb结合活性，维持或减少 对H型和R型FcγRIIa的两种同种异型的结合活性。还发现含有抗体Fc区的多肽含有替换Pro位于第238位（EU编号）与Asp和其他几种改变增强FcγRIIb结合 活动，并维持或减少对类型H和R的两种同种异型的结合活性。

    Method of modifying isoelectric point of antibody via amino acid substitution in CDR
    16.
    发明授权
    Method of modifying isoelectric point of antibody via amino acid substitution in CDR 有权
    通过CDR中氨基酸取代修饰抗体等电点的方法

    公开(公告)号：US09096651B2

    公开(公告)日：2015-08-04

    申请号：US12679922

    申请日：2008-09-26

    申请人： Tomoyuki Igawa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana ,  Taichi Kuramochi

    发明人： Tomoyuki Igawa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana ,  Taichi Kuramochi

    IPC分类号： A61K39/395 ,  C07K16/00

    CPC分类号： C07K16/2866 ,  A61K39/39591 ,  C07K16/00 ,  C07K16/28 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/732 ,  G01N33/6854

    摘要： Methods are described for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The disclosure also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies with a modified isoelectric point. The disclosure further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.

    摘要翻译： 描述了用于修饰抗体的等电点同时保留其抗原结合活性的方法，包括修饰互补决定区（CDR）表面上至少一个可暴露氨基酸残基的电荷。 本公开还提供了用于纯化多特异性抗体的方法，包括修饰等电点，以及用于改进具有修饰的等电点的抗体的血浆药代动力学的方法。 本公开进一步提供具有修饰的等电点的抗体，包含抗体作为活性成分的药物组合物，以及用于产生抗体和组合物的方法。

    Anti-glypican-3 antibody having improved kinetics in plasma
    17.
    发明授权
    Anti-glypican-3 antibody having improved kinetics in plasma 有权
    具有改善血浆动力学的抗磷脂酰肌醇蛋白聚糖-3抗体

    公开(公告)号：US08497355B2

    公开(公告)日：2013-07-30

    申请号：US12733933

    申请日：2008-09-26

    申请人： Tomoyuki Igawa ,  Taichi Kuramochi ,  Hirotake Shiraiwa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana ,  Takahiro Ishiguro

    发明人： Tomoyuki Igawa ,  Taichi Kuramochi ,  Hirotake Shiraiwa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana ,  Takahiro Ishiguro

    IPC分类号： C07K16/30 ,  A61K39/395 ,  C07H21/04 ,  C12P21/08 ,  C12N15/13

    CPC分类号： C07K16/2863 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/18 ,  C07K16/30 ,  C07K16/303 ,  C07K2317/14 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2317/94 ,  C12N15/8258

    摘要： A method of modulating the plasma half-life of anti-glypican 3 antibody, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody that has a plasma half-life that has been modulated, a method of preparing the anti-glypican 3 antibody and a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient are provided. Disclosed is a method of modulating the plasma half-life of anti-glypican 3 antibody by modifying an amino acid residue that is exposed on the surface of the anti-glypican 3 antibody; and anti-glypican 3 antibody that has a plasma half-life that has been modulated by amino acid residue modification, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody, and a method of preparing the anti-glypican 3 antibody and producing a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient.

    摘要翻译： 调节抗磷脂酰肌醇蛋白聚糖3抗体的血浆半衰期的方法，一种药物组合物，其包含具有调节的血浆半衰期的抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分，制备抗磷脂酰肌醇蛋白聚糖的方法 提供了包含抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分的药物组合物。 公开了通过改变暴露于抗磷脂酰肌醇蛋白聚糖3抗体表面的氨基酸残基来调节抗磷脂酰肌醇蛋白聚糖3抗体的血浆半衰期的方法; 和具有通过氨基酸残基修饰调节的血浆半衰期的抗磷脂酰肌醇蛋白聚糖3抗体，包含作为活性成分的磷脂酰肌醇蛋白聚糖3抗体的药物组合物，以及制备抗磷脂酰肌醇蛋白聚糖3抗体的方法和 制备包含抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分的药物组合物。

    ANTI-GLYPICAN-3 ANTIBODY HAVING IMPROVED KINETICS IN PLASMA
    19.
    发明申请
    ANTI-GLYPICAN-3 ANTIBODY HAVING IMPROVED KINETICS IN PLASMA 有权
    具有等离子体改善动力学的抗GLYPICAN-3抗体

    公开(公告)号：US20100239577A1

    公开(公告)日：2010-09-23

    申请号：US12733933

    申请日：2008-09-26

    申请人： Tomoyuki Igawa ,  Taichi Kuramochi ,  Hirotake Shiraiwa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana ,  Takahiro Ishiguro

    发明人： Tomoyuki Igawa ,  Taichi Kuramochi ,  Hirotake Shiraiwa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana ,  Takahiro Ishiguro

    IPC分类号： A61K39/395 ,  C07K16/18 ,  C07H21/00 ,  C12N5/10 ,  C12P21/02 ,  A61P35/00

    CPC分类号： C07K16/2863 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/18 ,  C07K16/30 ,  C07K16/303 ,  C07K2317/14 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2317/94 ,  C12N15/8258

    摘要： A method of modulating the plasma half-life of anti-glypican 3 antibody, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody that has a plasma half-life that has been modulated, a method of preparing the anti-glypican 3 antibody and a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient are provided. Disclosed is a method of modulating the plasma half-life of anti-glypican 3 antibody by modifying an amino acid residue that is exposed on the surface of the anti-glypican 3 antibody; and anti-glypican 3 antibody that has a plasma half-life that has been modulated by amino acid residue modification, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody, and a method of preparing the anti-glypican 3 antibody and producing a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient.

    摘要翻译： 调节抗磷脂酰肌醇蛋白聚糖3抗体的血浆半衰期的方法，一种药物组合物，其包含具有调节的血浆半衰期的抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分，制备抗磷脂酰肌醇蛋白聚糖的方法 提供了包含抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分的药物组合物。 公开了通过改变暴露于抗磷脂酰肌醇蛋白聚糖3抗体表面的氨基酸残基来调节抗磷脂酰肌醇蛋白聚糖3抗体的血浆半衰期的方法; 和具有通过氨基酸残基修饰调节的血浆半衰期的抗磷脂酰肌醇蛋白聚糖3抗体，包含作为活性成分的磷脂酰肌醇蛋白聚糖3抗体的药物组合物，以及制备抗磷脂酰肌醇蛋白聚糖3抗体的方法和 制备包含抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分的药物组合物。